Long-term safety and efficacy of tezepelumab in people with severe, uncontrolled asthma (DESTINATION): a randomised, placebo-controlled extension study
Published 2023 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Long-term safety and efficacy of tezepelumab in people with severe, uncontrolled asthma (DESTINATION): a randomised, placebo-controlled extension study
Authors
Keywords
-
Journal
Lancet Respiratory Medicine
Volume -, Issue -, Pages -
Publisher
Elsevier BV
Online
2023-01-24
DOI
10.1016/s2213-2600(22)00492-1
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Dupilumab reduces oral corticosteroid use in patients with corticosteroid-dependent severe asthma: An analysis of the phase 3, open-label extension TRAVERSE trial
- (2022) Lawrence D. Sher et al. CHEST
- Evaluation of the oral corticosteroid-sparing effect of tezepelumab in adults with oral corticosteroid-dependent asthma (SOURCE): a randomised, placebo-controlled, phase 3 study
- (2022) Michael E Wechsler et al. Lancet Respiratory Medicine
- Reduction in asthma admissions during the COVID-19 pandemic: consequence of public health measures in Singapore
- (2021) Liang En Wee et al. EUROPEAN RESPIRATORY JOURNAL
- Tezepelumab in Adults and Adolescents with Severe, Uncontrolled Asthma
- (2021) Andrew Menzies-Gow et al. NEW ENGLAND JOURNAL OF MEDICINE
- Functionality and Performance of an Accessorized Pre-Filled Syringe and an Autoinjector for At-Home Administration of Tezepelumab in Patients with Severe, Uncontrolled Asthma
- (2021) Sady Alpizar et al. Journal of Asthma and Allergy
- Effect of tezepelumab on airway inflammatory cells, remodelling, and hyperresponsiveness in patients with moderate-to-severe uncontrolled asthma (CASCADE): a double-blind, randomised, placebo-controlled, phase 2 trial
- (2021) Sarah Diver et al. Lancet Respiratory Medicine
- Thymic stromal lymphopoietin: its role and potential as a therapeutic target in asthma
- (2020) Gail M. Gauvreau et al. EXPERT OPINION ON THERAPEUTIC TARGETS
- Long-term Safety and Clinical Benefit of Mepolizumab in Patients With the Most Severe Eosinophilic Asthma: the COSMEX Study
- (2019) Sandhya Khurana et al. CLINICAL THERAPEUTICS
- Asthma, asthma control and risk of acute myocardial infarction: HUNT study
- (2019) Aivaras Cepelis et al. EUROPEAN JOURNAL OF EPIDEMIOLOGY
- Tralokinumab for severe, uncontrolled asthma (STRATOS 1 and STRATOS 2): two randomised, double-blind, placebo-controlled, phase 3 clinical trials
- (2018) Reynold A Panettieri et al. Lancet Respiratory Medicine
- Associations of Asthma and Asthma Control With Atrial Fibrillation Risk
- (2018) Aivaras Cepelis et al. JAMA Cardiology
- Tezepelumab, an anti-TSLP monoclonal antibody, in the treatment of moderate to severe atopic dermatitis: A randomized phase 2a clinical trial
- (2018) Eric L. Simpson et al. JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY
- Long-term safety and efficacy of benralizumab in patients with severe, uncontrolled asthma: 1-year results from the BORA phase 3 extension trial
- (2018) William W Busse et al. Lancet Respiratory Medicine
- Cardiovascular and cerebrovascular events among patients receiving omalizumab: Results from EXCELS, a prospective cohort study in moderate to severe asthma
- (2017) Carlos Iribarren et al. JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY
- Tezepelumab in Adults with Uncontrolled Asthma
- (2017) Jonathan Corren et al. NEW ENGLAND JOURNAL OF MEDICINE
- Adult Asthma and Risk of Coronary Heart Disease, Cerebrovascular Disease, and Heart Failure: A Prospective Study of 2 Matched Cohorts
- (2012) C. Iribarren et al. AMERICAN JOURNAL OF EPIDEMIOLOGY
- Asthma outcomes: Pulmonary physiology
- (2012) Robert S. Tepper et al. JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY
Publish scientific posters with Peeref
Peeref publishes scientific posters from all research disciplines. Our Diamond Open Access policy means free access to content and no publication fees for authors.
Learn MoreBecome a Peeref-certified reviewer
The Peeref Institute provides free reviewer training that teaches the core competencies of the academic peer review process.
Get Started